Literature DB >> 17916765

Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials.

Jeffrey L Saver1.   

Abstract

BACKGROUND AND
PURPOSE: Stroke treatments are generally not curative, but rather alter patient outcome over the entire range of functional measures. Dichotomizing outcome scales reduces computational complexity, but discards substantial outcome information, artificially privileges only a single health state transition as clinically meaningful, and often reduces study power. Newer approaches to endpoint analysis have several advantageous properties. Summary of Review- The global statistic assesses treatment effects on multiple outcome measures simultaneously. However, translating the global statistic multidimensional vector effect at the population level into benefit or harm expected in the individual patient is problematic. Responder analysis adjusts outcome thresholds to patient stroke severity at study entry, identifying achievable goals for each patient. However, responder analysis still discards substantial outcome information. Shift analysis gauges change in outcome distributions over the full range of ascertained outcomes, incorporating benefit and harm at all health state transitions valued by patients and clinicians, and often increasing study power. Translation of findings of shift analyses into clinically accessible terms may be accomplished using the recently developed joint outcome table specification technique, which yields the following values for the number needed to treat for 1 patient to improve in a clinically important manner: nimodipine in subarachnoid hemorrhage, 6.8; coiling over clipping, 5.9; intra-arterial pro-urokinase in acute cerebral ischemia, 4.8; intravenous tissue plasminogen activator, 3.3.
CONCLUSIONS: Dichotomized, global statistic, responder, and shift analyses each offer distinctive benefits and drawbacks. Choice of primary end point analytic technique should be tailored to the study population, expected treatment response, and study purpose. Shift analysis generally provides the most comprehensive index of a treatment's clinical impact.

Entities:  

Mesh:

Year:  2007        PMID: 17916765     DOI: 10.1161/STROKEAHA.107.488536

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  68 in total

1.  Italian guidelines on thrombolysis indications in ischaemic stroke have been revised after IST 3 trial and Cochrane Review: PROS.

Authors:  Stefano Ricci; Silvia Cenciarelli; Tatiana Mazzoli
Journal:  Intern Emerg Med       Date:  2013-08-23       Impact factor: 3.397

2.  Why don't more patients receive intravenous rt-PA for acute stroke?

Authors:  Patrick Lyden
Journal:  Expert Rev Neurother       Date:  2015-05-04       Impact factor: 4.618

3.  Refining Prognosis for Intracerebral Hemorrhage by Early Reassessment.

Authors:  Matthew B Maas; Brandon A Francis; Rajbeer S Sangha; Bryan D Lizza; Eric M Liotta; Andrew M Naidech
Journal:  Cerebrovasc Dis       Date:  2017-01-04       Impact factor: 2.762

Review 4.  Clinical trial design in the neurocritical care unit.

Authors:  C E Hall; M Mirski; Y Y Palesch; M N Diringer; A I Qureshi; C S Robertson; R Geocadin; C A C Wijman; P D Le Roux; Jose I Suarez
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

5.  Fixed Compared With Autoregulation-Oriented Blood Pressure Thresholds After Mechanical Thrombectomy for Ischemic Stroke.

Authors:  Nils H Petersen; Andrew Silverman; Sumita M Strander; Sreeja Kodali; Anson Wang; Lauren H Sansing; Joseph L Schindler; Guido J Falcone; Emily J Gilmore; Adam S Jasne; Branden Cord; Ryan M Hebert; Michele Johnson; Charles C Matouk; Kevin N Sheth
Journal:  Stroke       Date:  2020-02-12       Impact factor: 7.914

6.  Ischaemic stroke and thrombolysis: ask the onset time, not the age!

Authors:  Silvia Cenciarelli; Tatiana Mazzoli; Stefano Ricci
Journal:  Intern Emerg Med       Date:  2012-11-25       Impact factor: 3.397

Review 7.  SAHIT Investigators--on the outcome of some subarachnoid hemorrhage clinical trials.

Authors:  R Loch Macdonald; Blessing Jaja; Michael D Cusimano; Nima Etminan; Daniel Hanggi; David Hasan; Don Ilodigwe; Hector Lantigua; Peter Le Roux; Benjamin Lo; Ada Louffat-Olivares; Stephan Mayer; Andrew Molyneux; Audrey Quinn; Tom A Schweizer; Thomas Schenk; Julian Spears; Michael Todd; James Torner; Mervyn D I Vergouwen; George K C Wong; Jeff Singh
Journal:  Transl Stroke Res       Date:  2013-01-07       Impact factor: 6.829

8.  Metaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Yeon Gyoe Jang; Don Ilodigwe; R Loch Macdonald
Journal:  Neurocrit Care       Date:  2008-09-23       Impact factor: 3.210

9.  Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis.

Authors:  Jigneshkumar Gadhia; Sidney Starkman; Bruce Ovbiagele; Latisha Ali; David Liebeskind; Jeffrey L Saver
Journal:  Stroke       Date:  2010-01-07       Impact factor: 7.914

10.  Comparison of outcomes following thrombolytic therapy among patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA).

Authors:  Nishant Kumar Mishra; Stephen M Davis; Markku Kaste; Kennedy R Lees
Journal:  Diabetes Care       Date:  2010-09-15       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.